5 Key Takeaways

• 1

  Oculis CEO Riad Sherif described privosegtor (OCS-05) as a neuroprotective candidate being developed for optic neuritis and nonarteritic anterior ischemic optic neuropathy.

• 2

  In the phase 2 ACUITY trial, privosegtor improved vision by 18 letters compared with steroids alone, according to Sherif.

• 3

  Sherif said privosegtor improved or preserved retinal anatomy by preserving retinal ganglion cells and reduced neurofilament release, indicating less axonal damage.

• 4

  The phase 3 PIONEER program includes PIONEER-1 in optic neuritis, which has started enrolling patients, and PIONEER-2 and PIONEER-3, which are planned to start later.

• 5

  Sherif described the PIONEER program as a long-term commitment to neuro-ophthalmology and collaboration with the specialty community in the United States and other countries.